Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | CSF1R | P07333 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | FLT4 | P35916 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 16/20 | 0.68 |
| ▸ | BRAF | P15056 | 3/20 | 0.67 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607678 | 0.88 | KIT (0.64) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3865259 | 0.85 | KIT (0.68) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3867646 | 0.84 | KIT (0.67) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL2489551 | 0.84 | ABL1 (0.78) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3865275 | 0.83 | RXFP1 (0.72) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3865996 | 0.83 | ABL1 (0.76) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3866257 | 0.83 | KIT (0.76) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL5900627 | 0.83 | ABL1 (0.72) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL4038122 | 0.83 | FLT1 (0.75) | KITABL1EGFRCSF1RPDGFRB | |
| SCHEMBL4976103 | 0.82 | KDR (1.00) | KITABL1EGFRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7148357-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| CN-1671666-A | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridine compounds | SCHERING AG (DE) | 2005-09-21 | — | — | CN | disclosed |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | FLT4, KDR, FLT1 | KIT 80/4885ABL1 340/4885EGFR 20/4885 |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | KIT 28/4885ABL1 78/4885EGFR 23/4885 |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | KIT 28/4885ABL1 78/4885EGFR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.